ReviewEndocrinology and metabolism (Seoul, Korea)2014
Transcriptional regulation of fibroblast growth factor 21 expression.
Review in Endocrinology and metabolism (Seoul, Korea), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Research progress on the role of FGF21 in insulin resistance.Frontiers in endocrinology · 2025Review
- Glucosamine Enhancement of Learning and Memory Functions by Promoting Fibroblast Growth Factor 21 Production.International journal of molecular sciences · 2024Article
- Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects.Genes · 2021Article
- Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome.Scientific reports · 2021Observational
- Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine.Frontiers in endocrinology · 2021Review
- The Presence of Urinary Ketones according to Metabolic Status and Obesity.Journal of Korean medical science · 2020Article
- Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges.International journal of molecular sciences · 2019Review
- Spontaneous ketonuria and risk of incident diabetes: a 12 year prospective study.Diabetologia · 2019Observational
- Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction.Theranostics · 2018Article
- Anti-inflammatory effects of exercise training in adipose tissue do not require FGF21.The Journal of endocrinology · 2017Article
- Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury.Scientific reports · 2016Article
- Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles.Endocrine · 2016Article
- The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis.Endocrinology and metabolism (Seoul, Korea) · 2016Review
- Article
- Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases.Journal of diabetes research · 2016Review
- Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.Molecular endocrinology (Baltimore, Md.) · 2015Review
- Articles in 'endocrinology and metabolism' in 2014.Endocrinology and metabolism (Seoul, Korea) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast growth factor 21 (FGF21) is an attractive target for treating metabolic disease due to its wide-ranging beneficial effects on glucose and lipid metabolism. Circulating FGF21 levels are increased in insulin-resistant states; however, endogenous FGF21 fails to improve glucose and lipid metabolism in obesity, suggesting that metabolic syndrome is an FGF21-resistant state. Therefore, transcription factors for FGF21 are potential drug targets that could increase FGF21 expression in obesity and reduce FGF21 resistance. Despite many studies on the metabolic effects of FGF21, the transcriptional regulation of FGF21 gene expression remains controversial and is not fully understood. As the FGF21 transcription factor pathway is one of the most promising targets for the treatment of metabolic syndrome, further investigation of FGF21 transcriptional regulation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.